Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenal Gland Disorders

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026

Same author

Long-term follow-up of autoimmune polyendocrine syndrome type 1 in Norway.

The Journal of clinical endocrinology and metabolism·2026

Same author

Aire-dependent interferon signalling shapes thymocyte maturation and central tolerance in mice.

Communications biology·2025

Same author

EndoCompass Project: Research Roadmap for Adrenal and Cardiovascular Endocrinology.

Hormone research in paediatrics·2025

Same author

Immune Checkpoint Inhibitor Endocrinopathies-Insights From 3 Unusual Cases.

JCEM case reports·2025

Same author

EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology.

European journal of endocrinology·2025

Search research articles

Related Experiment Videos

Replacement therapy for Addison's disease: recent developments.

Kristian Løvås¹, Eystein S Husebye

¹University of Bergen, Institute of Medicine, Section of Endocrinology, 5021 Bergen, Norway. Kristian.lovas@helse-bergen.no

Expert Opinion on Investigational Drugs

|March 28, 2008

Summary

This summary is machine-generated.

Current Addison's disease treatments don't fully restore hormone levels, impacting quality of life. New therapies like timed-release hydrocortisone show promise for better patient outcomes.

Related Experiment Videos

Area of Science:

Endocrinology
Internal Medicine

Background:

Addison's disease (primary adrenal insufficiency) involves hormone deficiencies.
Conventional oral glucocorticoid and mineralocorticoid replacement fails to mimic physiological hormone levels and biorhythms.
Patients report impaired health-related quality of life (HRQoL) and increased mortality despite current treatments.

Purpose of the Study:

To review literature and recent developments in hormone replacement therapy for Addison's disease.
To provide expert opinion on optimal treatment strategies and future research directions.

Main Methods:

Literature review of existing studies and recent advancements.
Analysis of current replacement therapies including fludrocortisone and glucocorticoids.
Evaluation of novel treatment modalities and potential androgen replacement.

Main Results:

Standard treatment involves fludrocortisone and divided doses of hydrocortisone or cortisone acetate.
Synthetic glucocorticoids may have long-term metabolic side effects, questioning their first-line suitability.
Timed-release hydrocortisone and continuous subcutaneous hydrocortisone infusion are emerging as promising options.

Conclusions:

Mineralocorticoid replacement with fludrocortisone is essential.
Glucocorticoid dosing should be individualized, with caution regarding synthetic forms.
Further research is needed to confirm the benefits of dehydroepiandrosterone (DHEA) or testosterone replacement in selected Addison's disease patients.